Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. - Wikidata - wikimedia - TriplyDB

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.

http://www.wikidata.org/entity/Q34141180

about

Development and evaluation of different normalization strategies for gene expression studies in Candida albicans biofilms by real-time PCR Structural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14α-Demethylase.Real-time PCR in clinical microbiology: applications for routine laboratory testing.Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole Expanding the Binding Envelope of CYP51 Inhibitors TargetingTrypanosoma cruziwith 4-Aminopyridyl-Based Sulfonamide Derivatives Posaconazole: an oral triazole with an extended spectrum of activity Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis Fungal cytochrome P450 sterol 14α-demethylase (CYP51) and azole resistance in plant and human pathogens.Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing.Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.Inactivation of sterol Delta5,6-desaturase attenuates virulence in Candida albicans Amino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance.Resistance to antifungals that target CYP51.Structural basis for heterogeneous phenotype of ERG11 dependent Azole resistance in C.albicans clinical isolates Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2.Drug strategies targeting CYP51 in neglected tropical diseases In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.Fluconazole susceptibility and ERG11 gene expression in vaginal candida species isolated from Lagos Nigeria Conventional Morphology Versus PCR Sequencing, rep-PCR, and MALDI-TOF-MS for Identification of Clinical Aspergillus Isolates Collected Over a 2-Year Period in a University Hospital at Kayseri, Turkey.Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations.Resistance Surveillance in Candida albicans: A Five-Year Antifungal Susceptibility Evaluation in a Brazilian University Hospital.Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 Posaconazole: clinical pharmacology and potential for management of fungal infections.An update on antifungal targets and mechanisms of resistance in Candida albicans.A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity.Role of posaconazole in the management of oropharyngeal and esophageal candidiasis Posaconazole: a new broad-spectrum antifungal agent.Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates.Posaconazole in the management of refractory invasive fungal infections.Efflux-mediated antifungal drug resistance.Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications.Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p.Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.The effect of biomaterials and antifungals on biofilm formation by Candida species: a review.Update on mechanisms of azole resistance in Mycosphaerella graminicola and implications for future control.

P2860

Q24670742-06C76EC3-3AE1-464C-8E97-8FEACFC81AC7 Q27324352-ECEBF014-7E53-4668-9A54-FE65FCD20BC6 Q27472851-249FD192-A22E-4078-AA4E-52901EA6535C Q27660510-895A66CB-5A4E-4E80-8696-90E89FAE3EC8 Q27683570-1E04C44D-8D81-4A2F-9D70-0A5F746AF85A Q28291282-83C5769A-9CCC-49F2-954E-0EC2E46D8342 Q28818603-D4DCDABB-F821-47CF-B50D-F4CC2F0BD466 Q30318077-9C6401CD-817C-4F86-989B-A6C8AD818666 Q33493582-0EF01D79-6966-47E0-906E-0880CCB2B665 Q33622915-0D871792-A310-4613-8AFE-37E150EE8A52 Q33876638-2E0B58C3-773F-45C2-B48D-E85A660AAC7E Q33935383-BA57E71D-1E6D-4159-AC6E-AADF31EC3D8D Q33940714-82B60876-3F37-487F-9B59-31B201CA19E7 Q34276700-C1C854B8-64D9-4C01-AA8B-50B9553FB799 Q34543717-58E79C60-4D51-4226-BAF0-8931686D62F2 Q34561878-CFA4CB34-2FF0-4FFE-AB74-BAFBCA5269D3 Q34622554-7592AAFE-8CE3-48F4-A7DB-15F87224DF01 Q34680661-8DB240CB-20CC-47C6-8234-D81031EA073B Q35759045-B1E6EFBD-F0E2-40D3-9545-BEB5D422731C Q35806201-EB72FF72-73BC-40D2-87D9-7F8FE7C04A6F Q35862713-8978715E-058C-4B4B-9B5F-F4D0F4DEB06D Q35939584-896D7C54-BE72-4C18-9271-F198CD648458 Q36008037-4B933D9B-89B5-4808-AFA8-71D66FB297B5 Q36077230-C2C8D0C6-95A9-41D6-A3E2-C3D05E4FE746 Q36172242-9355A0D8-EC9E-4006-8BA9-0F10691699E3 Q36233491-06991D56-5469-4C1F-8AFD-239F703B81DA Q36235037-74D98E4E-2892-4E6E-B2FF-205EEDB7C166 Q36589292-F4A62175-78FC-4C81-B524-7A13165F3CEC Q36642964-724F33E2-8A0B-49C0-8D4B-2A47CF677F52 Q36828159-C649F100-CD24-4CFC-91C6-A93772AD32A9 Q36921520-9239EFE1-0EE0-47C2-98A2-D67236FB0ADF Q36949532-E32D7852-4A56-46CF-92D2-A61FE77B0A8E Q37052755-2CFE5298-668F-4C83-B4FE-CE4CC183BB64 Q37156645-56282C2C-F547-4E1F-AF7B-0C1D673070AF Q37263791-BD084D78-A7F1-42F7-B40A-7890AF48A816 Q37337658-4555D261-1496-4586-8A96-26F5F961C497 Q37450682-77204360-6AC8-4A05-893E-737D0B10C469 Q37568607-323FCEF0-222F-492A-A0DE-612BDDA488B2 Q38009721-8037E707-E7CF-46F7-951C-09F71EA71C9F Q38021430-AA7193C4-06CF-4BE1-BE88-468284CB08B5

P2860

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.

http://www.wikidata.org/entity/Q34141180

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Application of real-time quant ...... uced susceptibility to azoles.

@ast

Application of real-time quant ...... uced susceptibility to azoles.

@en

Application of real-time quant ...... uced susceptibility to azoles.

@nl

type

label

Application of real-time quant ...... uced susceptibility to azoles.

@ast

Application of real-time quant ...... uced susceptibility to azoles.

@en

Application of real-time quant ...... uced susceptibility to azoles.

@nl

prefLabel

Application of real-time quant ...... uced susceptibility to azoles.

@ast

Application of real-time quant ...... uced susceptibility to azoles.

@en

Application of real-time quant ...... uced susceptibility to azoles.

@nl

P1433

Q34141180-5404C055-F253-4104-821D-2320C38C7863

P1476

Q34141180-B78CDE22-B784-4303-9760-653EF4244F2C

P2093

Q34141180-27479970-C6C3-4BB5-A76A-98BF41C22196

Q34141180-582A2941-1EE3-4AAA-B096-8B66127576D2

Q34141180-75C25052-6CFD-487F-A06D-DC01FDBCE9B3

Q34141180-925DD4B5-1EA2-4871-BAF8-0C0A06F5EC66

Q34141180-BB7B25E2-5382-40D3-8112-017088780FA9

P2860

Q34141180-1569E97D-DE6F-4C2A-ABE3-7966F1EB4BF5

Q34141180-19559D00-472E-4C80-AFDB-087DC39C8F94

Q34141180-1DA707EF-841E-4914-840C-D7D3B1F4D92D

Q34141180-38D05E72-932F-4F68-8A45-850E65F246B2

Q34141180-45E92E07-BB77-4ED4-8FB9-341407B8D595

Q34141180-51923AD1-6104-4E0F-802F-256706F6BCB6

Q34141180-56B5E1E4-1287-4C4D-AE42-00D09C5AB999

Q34141180-578DB4E4-1AD9-4C68-AB74-A126AE942D02

Q34141180-60AE6523-2241-4C90-B27E-D10045113798

Q34141180-61693E17-5798-4F98-AF31-8BC21437B27B

P304

Q34141180-1947DDAE-4856-417C-B7EF-D1A5F19658AA

P31

Q34141180-C77CCA08-792A-413F-900F-51D61ECAA77C

P356

Q34141180-4C1DF221-9CFA-4023-8694-6F329E32B928

P407

Q34141180-52057FA6-154F-498E-8D6D-209ED8AA32BB

P433

Q34141180-827D7F24-AD52-4E42-977C-F4D109542DAB

P478

Q34141180-4D7855FE-FD98-4BD8-9B58-0801A4D7F334

P577

Q34141180-176A6063-9FF4-40E3-97CC-5981EA4C9793

P5875

Q34141180-058B6097-78C2-4BCE-880A-75BC8FAC53D9

P698

Q34141180-1D59EEA4-B0EC-48FA-A1A4-8AC11132D2E4

P932

Q34141180-3D2E75F4-4A32-4693-9823-5E8E29712970

P356

AAC.48.6.2124-2131.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Application of real-time quant ...... uced susceptibility to azoles.

@en

P2093

Andrew S Chau

http://www.w3.org/2001/XMLSchema#string

Cara A Mendrick

http://www.w3.org/2001/XMLSchema#string

David Loebenberg

http://www.w3.org/2001/XMLSchema#string

Frank J Sabatelli

http://www.w3.org/2001/XMLSchema#string

Paul M McNicholas

http://www.w3.org/2001/XMLSchema#string

P2860

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.

Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR.

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients

Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis

Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.

Antifungal drug resistance to azoles and polyenes.

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

P304

2124-2131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.6.2124-2131.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8551559

http://www.w3.org/2001/XMLSchema#string

P698

15155210

http://www.w3.org/2001/XMLSchema#string

P932

415610

http://www.w3.org/2001/XMLSchema#string